AI Analysis
AI-generated analysis. Always verify with the original filing.
Intensifying losses and cash burn marked FY2025 for this clinical-stage biotech, driven by R&D ramp for later-stage ficerafusp alfa trials amid no revenue since 2018 inception, buffered by equity financing from common stock sales.
Key Takeaways
1Net income was -$137.9M, a -102.9% change from -$68.0M prior year, reflecting higher development costs for therapeutic candidates advancing to later clinical stages with larger trials.
2Net cash provided by operating activities was -$106.8M versus -$74.8M prior year, consistent with significant operating losses and negative cash flows from operations.
3Free cash flow was -$107.1M, calculated as operating cash flow less capital expenditures, highlighting cash consumption in pre-revenue development.
4No revenue generated since December 2018 inception, with operations funded through equity sales including under the ATM Program as market conditions permit.